American Public Education's third quarter marked a milestone: it was the first full period operating under a single institution, American Public University System, following the completion of its institutional combination in early August 2026. That restructuring is central to the company's long-range plan, making this report a key checkpoint on execution. The results also land amid a mixed backdrop for postsecondary education providers, where enrollment trends, federal funding dynamics, and rising marketing costs are closely watched. For investors, the quarter offered an early read on whether APEI can sustain momentum in its Health+ segment while navigating temporary headwinds in Military+ tied to active-duty deployments and a revenue timing shift. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
For the three months ended September 30, 2026, American Public Education reported consolidated revenue of $169.1 million, a 3.6% year-over-year increase from $163.2 million. Excluding revenue from Graduate School USA (GSUSA), which was sold in July 2025, revenue would have risen 4.2%. The top line also absorbed an approximately $6.0 million shift into the fourth quarter related to Military+ registration timing.
Net income available to common stockholders increased 6.0% to $5.9 million, while diluted EPS rose 6.7% to $0.32 from $0.30. Both figures beat the roughly $0.26 consensus estimate. Adjusted EBITDA came in at $17.5 million, down from $20.7 million a year earlier, reflecting the revenue shift, a $5.7 million increase in selling and promotional expense, and investments in marketing optimization and integration. The company noted that revenue, net income, adjusted EBITDA, and diluted EPS all exceeded its own guidance ranges.
By segment, Health+ revenue grew 9.0% to $86.4 million, while Military+ revenue decreased 0.5% to $82.7 million. Health+ total student enrollment rose 2.5% to 19,100, and Military+ net course registrations increased 3.8% to 103,800. From what I see, the segment trends highlight steady progress in Health+ even as Military+ faced a one-time timing issue.
The third quarter report landed as a "beat-and-raise" quarter, with results topping both consensus estimates and management's guidance, alongside an upward revision to full-year outlook. That combination is generally viewed constructively by investors, particularly given the successful completion of the institutional combination. However, the year-over-year decline in adjusted EBITDA and the weaker operating cash flow of $11.8 million, down from $21.7 million a year earlier, are points of focus. Management attributed the cash flow dip to what it believes is a temporary implementation issue related to Title IV disbursements following the combination, but investors will be watching for a normalization in the quarters ahead.
American Public Education raised its full-year 2026 guidance across every key metric. The company now expects revenue of $695.0 million to $701.0 million, up from $690.0 million to $698.0 million, and diluted EPS of $2.59 to $2.84, versus $2.48 to $2.79 previously. Adjusted EBITDA guidance moved to $98.0 million to $105.0 million, and capital expenditures were guided lower, to $23.0 million to $26.0 million.
For the fourth quarter, management is guiding to revenue of $179.4 million to $185.4 million and diluted EPS of $0.81 to $1.07, reflecting the anticipated recovery of the roughly $6.0 million in Military+ revenue that shifted out of the third quarter.
Looking ahead, investors should monitor several themes. First, the pace of Health+ enrollment growth and the effectiveness of marketing optimization efforts, which management expects to improve in the fourth quarter. Second, the resolution of the Title IV cash flow timing issue and whether operating cash flow normalizes. Third, any developments on the potential increase in military tuition assistance reimbursement rates, which could affect Military+ pricing. Finally, continued execution on campus expansion and the company's cost-synergy plans following the institutional combination will be central to its multi-year revenue and margin targets. I’m watching this closely as the company moves into the final quarter.
In my own work, I often turn to Tickeron’s AI Screener to quickly filter education-sector names and compare fundamentals or technical signals across peers. It helps surface ideas without spending hours on manual screens, and I find the customizable filters particularly useful when evaluating names like APEI after earnings. The tool keeps the process efficient while highlighting potential setups worth further review.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
APEI moved below its 50-day moving average on October 28, 2026 date and that indicates a change from an upward trend to a downward trend. In 25 of 32 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 78%.
The Momentum Indicator moved below the 0 level on October 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on APEI as a result. In 63 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for APEI turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 30 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
The 10-day moving average for APEI crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APEI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where APEI's RSI Oscillator exited the oversold zone, 19 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where APEI advanced for three days, in 253 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
APEI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 216 of 281 cases where APEI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 62 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. APEI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.172) is normal, around the industry mean (1.158). P/E Ratio (14.912) is within average values for comparable stocks, (8.484). Projected Growth (PEG Ratio) (0.888) is also within normal values, averaging (1.327). Dividend Yield (0.000) settles around the average of (4.151) among similar stocks. P/S Ratio (1.252) is also within normal values, averaging (27.566).
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of online post-secondary education
Industry OtherConsumerSpecialties